Home LiteratureArticle Details
PMID: 26466568 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.

Nature ·Vol. 526 ·No. 7575 ·2015-10-29 ·Pages 700-4

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Gloeckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F, Thomas RK, Fischer M

Abstract

Neuroblastoma is a malignant paediatric tumour of the sympathetic nervous system. Roughly half of these tumours regress spontaneously or are cured by limited therapy. By contrast, high-risk neuroblastomas have an unfavourable clinical course despite intensive multimodal treatment, and their molecular basis has remained largely elusive. Here we have performed whole-genome sequencing of 56 neuroblastomas (high-risk, n = 39; low-risk, n = 17) and discovered recurrent genomic rearrangements affecting a chromosomal region at 5p15.33 proximal of the telomerase reverse transcriptase gene (TERT). These rearrangements occurred only in high-risk neuroblastomas (12/39, 31%) in a mutually exclusive fashion with MYCN amplifications and ATRX mutations, which are known genetic events in this tumour type. In an extended case series (n = 217), TERT rearrangements defined a subgroup of high-risk tumours with particularly poor outcome. Despite a large structural diversity of these rearrangements, they all induced massive transcriptional upregulation of TERT. In the remaining high-risk tumours, TERT expression was also elevated in MYCN-amplified tumours, whereas alternative lengthening of telomeres was present in neuroblastomas without TERT or MYCN alterations, suggesting that telomere lengthening represents a central mechanism defining this subtype. The 5p15.33 rearrangements juxtapose the TERT coding sequence to strong enhancer elements, resulting in massive chromatin remodelling and DNA methylation of the affected region. Supporting a functional role of TERT, neuroblastoma cell lines bearing rearrangements or amplified MYCN exhibited both upregulated TERT expression and enzymatic telomerase activity. In summary, our findings show that remodelling of the genomic context abrogates transcriptional silencing of TERT in high-risk neuroblastoma and places telomerase activation in the centre of transformation in a large fraction of these tumours.

MeSH Terms
Cell Line, Tumor Cell Transformation, Neoplastic/genetics Chromatin/genetics,metabolism Chromosomes, Human, Pair 5/genetics DNA Helicases/genetics DNA Methylation Enhancer Elements, Genetic/genetics Enzyme Activation/genetics Gene Amplification/genetics Gene Expression Regulation, Neoplastic/genetics Gene Silencing Genome, Human/genetics Humans Infant N-Myc Proto-Oncogene Protein Neuroblastoma/classification,enzymology,genetics,pathology Nuclear Proteins/genetics Oncogene Proteins/genetics Prognosis RNA, Messenger/analysis,genetics Recombination, Genetic/genetics Risk Telomerase/genetics,metabolism Translocation, Genetic/genetics Up-Regulation/genetics X-linked Nuclear Protein
Chemicals
Chromatin MYCN protein, human N-Myc Proto-Oncogene Protein Nuclear Proteins Oncogene Proteins RNA, Messenger TERT protein, human Telomerase DNA Helicases ATRX protein, human X-linked Nuclear Protein
Authors & Affiliations
55 authors, click to expand affiliations / ORCID
Peifer Martin
Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany. | Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Hertwig Falk
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. | Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Roels Frederik
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. | Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Dreidax Daniel
Division Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Gartlgruber Moritz
Division Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Menon Roopika
Department of Prostate Cancer Research, Institute of Pathology, Center for Integrated Oncology Cologne-Bonn, University Hospital of Bonn, 53127 Bonn, Germany. | NEO New Oncology AG, 51105 Cologne, Germany.
Krämer Andrea
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. | Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Roncaioli Justin L
Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute (UPCI), Hillman Cancer Center, Pittsburgh, Pennsylvania 15213, USA.
Sand Frederik
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Heuckmann Johannes M
NEO New Oncology AG, 51105 Cologne, Germany.
Ikram Fakhera
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. | Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany. | Cologne Center for Genomics, University of Cologne, 50931 Cologne, Germany.
Schmidt Rene
Institute of Biostatistics and Clinical Research, University of Münster, 48149 Münster, Germany.
Ackermann Sandra
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. | Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Engesser Anne
Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Kahlert Yvonne
Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Vogel Wenzel
Department of Prostate Cancer Research, Institute of Pathology, Center for Integrated Oncology Cologne-Bonn, University Hospital of Bonn, 53127 Bonn, Germany.
Altmüller Janine
Cologne Center for Genomics, University of Cologne, 50931 Cologne, Germany.
Nürnberg Peter
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. | Cologne Center for Genomics, University of Cologne, 50931 Cologne, Germany. | Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, 50931 Cologne, Germany.
Thierry-Mieg Jean
National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland 20894, USA.
Thierry-Mieg Danielle
National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland 20894, USA.
Mariappan Aruljothi
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Heynck Stefanie
NEO New Oncology AG, 51105 Cologne, Germany.
Mariotti Erika
NEO New Oncology AG, 51105 Cologne, Germany.
Henrich Kai-Oliver
Division Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Gloeckner Christian
NEO New Oncology AG, 51105 Cologne, Germany.
Bosco Graziella
Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
Leuschner Ivo
Department of Pathology, University of Kiel, 24118 Kiel, Germany.
Schweiger Michal R
Functional Epigenomics, University of Cologne, 50931 Cologne, Germany.
Savelyeva Larissa
Division Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Watkins Simon C
Department of Cell Biology, Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
Shao Chunxuan
Division of Theoretical Systems Biology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Bell Emma
Division Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Höfer Thomas
Division of Theoretical Systems Biology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Achter Viktor
Computing Center, University of Cologne, 50931 Cologne, Germany.
Lang Ulrich
Computing Center, University of Cologne, 50931 Cologne, Germany. | Department of Informatics, University of Cologne, 50931 Cologne, Germany.
Theissen Jessica
Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Volland Ruth
Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Saadati Maral
Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Eggert Angelika
Department of Pediatric Oncology and Hematology, Charité University Medical Center Berlin, 10117 Berlin, Germany.
de Wilde Bram
Center for Medical Genetics, Ghent University, 9000 Ghent, Belgium.
Berthold Frank
Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Peng Zhiyu
BGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong, 518083 China.
Zhao Chen
Center for Pharmacogenomics and Fudan-Zhangjiang Center for Clinical Genomics, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology School of Pharmacy and School of Life Sciences, Fudan University, Shanghai 201203, China.
Shi Leming
Center for Pharmacogenomics and Fudan-Zhangjiang Center for Clinical Genomics, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology School of Pharmacy and School of Life Sciences, Fudan University, Shanghai 201203, China.
Ortmann Monika
Department of Pathology, University of Cologne, 50937 Cologne, Germany.
Büttner Reinhard
Department of Pathology, University of Cologne, 50937 Cologne, Germany.
Perner Sven
Department of Prostate Cancer Research, Institute of Pathology, Center for Integrated Oncology Cologne-Bonn, University Hospital of Bonn, 53127 Bonn, Germany.
Hero Barbara
Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Schramm Alexander
Department of Pediatric Oncology and Hematology, University Children's Hospital, 45147 Essen, Germany.
Schulte Johannes H
Department of Pediatric Oncology and Hematology, Charité University Medical Center Berlin, 10117 Berlin, Germany. | German Cancer Consortium (DKTK), 10117 Berlin, Germany. | German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Herrmann Carl
Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, 69120 Heidelberg, Germany. | Bioquant Center, University of Heidelberg, 69120 Heidelberg, Germany. | Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
O'Sullivan Roderick J
Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute (UPCI), Hillman Cancer Center, Pittsburgh, Pennsylvania 15213, USA.
Westermann Frank
Division Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Thomas Roman K
Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany. | Department of Pathology, University of Cologne, 50937 Cologne, Germany.
Fischer Matthias
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. | Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany. | Max Planck Institute for Metabolism Research, 50931 Cologne, Germany.
References (29)
29 references, click to expand
  1. Direct recruitment of N-myc to target gene promoters.
    Mol Carcinog. 2000 Oct;29(2):76-86 PMID: 11074604
  2. Neuroblastoma: biological insights into a clinical enigma.
    Nat Rev Cancer. 2003 Mar;3(3):203-16 PMID: 12612655
  3. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.
    Nat Genet. 2007 Mar;39(3):311-8 PMID: 17277777
  4. Neuroblastoma.
    Lancet. 2007 Jun 23;369(9579):2106-20 PMID: 17586306
  5. A rapid micro chromatin immunoprecipitation assay (microChIP).
    Nat Protoc. 2008;3(6):1032-45 PMID: 18536650
  6. Identification of ALK as a major familial neuroblastoma predisposition gene.
    Nature. 2008 Oct 16;455(7215):930-5 PMID: 18724359
  7. Rearrangement of upstream sequences of the hTERT gene during cellular immortalization.
    Genes Chromosomes Cancer. 2009 Nov;48(11):963-74 PMID: 19672873
  8. Alternative lengthening of telomeres: models, mechanisms and implications.
    Nat Rev Genet. 2010 May;11(5):319-30 PMID: 20351727
  9. Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies.
    Blood. 2010 Aug 26;116(8):1317-20 PMID: 20460502
  10. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins.
    Nat Rev Cancer. 2011 Mar;11(3):161-76 PMID: 21346783
  11. Mapping and analysis of chromatin state dynamics in nine human cell types.
    Nature. 2011 May 5;473(7345):43-9 PMID: 21441907
  12. Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
    JAMA. 2012 Mar 14;307(10):1062-71 PMID: 22416102
  13. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.
    Nature. 2012 Mar 29;483(7391):589-93 PMID: 22367537
  14. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
    Nat Genet. 2013 Jan;45(1):12-7 PMID: 23202128
  15. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
    PLoS One. 2013;8(1):e52321 PMID: 23308108
  16. High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states.
    Nat Protoc. 2013 Mar;8(3):539-54 PMID: 23429716
  17. TERT promoter mutations in familial and sporadic melanoma.
    Science. 2013 Feb 22;339(6122):959-61 PMID: 23348503
  18. Highly recurrent TERT promoter mutations in human melanoma.
    Science. 2013 Feb 22;339(6122):957-9 PMID: 23348506
  19. The genetic landscape of high-risk neuroblastoma.
    Nat Genet. 2013 Mar;45(3):279-84 PMID: 23334666
  20. Master transcription factors and mediator establish super-enhancers at key cell identity genes.
    Cell. 2013 Apr 11;153(2):307-19 PMID: 23582322
  21. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
    Lancet Oncol. 2013 May;14(6):534-42 PMID: 23598174
  22. Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1.
    Nat Struct Mol Biol. 2014 Feb;21(2):167-74 PMID: 24413054
  23. Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases.
    Genes Chromosomes Cancer. 2013 Dec;52(12):1150-66 PMID: 24123354
  24. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.
    Nat Commun. 2014;5:3518 PMID: 24670920
  25. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma.
    Nature. 2014 Jul 24;511(7510):428-34 PMID: 25043047
  26. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
    J Neurooncol. 2014 Aug;119(1):17-26 PMID: 24792489
  27. The somatic genomic landscape of chromophobe renal cell carcinoma.
    Cancer Cell. 2014 Sep 8;26(3):319-30 PMID: 25155756
  28. Tissue-specific transcriptome sequencing analysis expands the non-human primate reference transcriptome resource (NHPRTR).
    Nucleic Acids Res. 2015 Jan;43(Database issue):D737-42 PMID: 25392405
  29. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.
    Genome Biol. 2015;16:133 PMID: 26109056
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
Published
2015-10-29
Epub
2015-00-14
Pages
700-4
Language
English
Region
England
NLM ID
0410462
PMCID
PMC4881306
Subset
IM
Grants
NCI NIH HHS · P30 CA047904 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]